Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats HIV-1 infection. Sold as Norvir, Ritonavir. Every FDA application for this active ingredient: 6 branded and 8 generic.
As of Nov 15, 2026, FDA lists 14 applications for Ritonavir (sold as Norvir, Ritonavir), first approved Mar 1, 1996, with 5 new uses approved and 0 published complete response letters.
First approved: Mar 1, 1996
Applications: 14
New uses approved: 5
Complete response letters: 0
Medicare spending, 2025: $5.0M
First approved in the EU: Aug 25, 1996
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Ritonavir
Part D
$4.5M
-29%
5,652
Norvir
Part D
$463K
-18%
229
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
RITONAVIR 100 MG TABLET: $0.608 per unitGeneric · -26% in a year
NORVIR 100 MG TABLET: $8.35 per unitBrand · +0% in a year
Approvals in the EU (EMA)
First approved in the EU 6 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Abbvie
Abbott
Cipla
Hikma
Mylan Pharms Inc